Kiadis Pharma

Beleggen in aandelen beurs Amsterdam, AEX en AMX index, etc.
Plaats reactie
Chouffe
Forum verkenner
Forum verkenner
Berichten: 90
Lid geworden op: 18 Okt 2017 08:34
waarderingen: 21
Contact:

Re: Kiadis Pharma

Berichtdoor Chouffe » 17 Apr 2018 10:07

vandaar de sprong dus vrijdag +10%. en zoals hierboven gemeld de (voorlopig) positieve cashpositie; en de koersdoel verhoging van Jefferies...
-----

Annual Results for the year ended December 31, 2017

- Significantly strengthened cash position;
- raised over EUR 60 million in equity and debt (gross, including raise in March 2018)
- Filed Marketing Authorization Application with the European Medicines Agency for ATIR101 in blood cancers
- Received Regenerative Medicine Advanced Therapy designation from the US FDA
- First patient enrolled in Phase 3 trial for ATIR101 in adult patients with blood cancer
- Leased existing commercial manufacturing facility in The Netherlands
- Strengthened Organization and Supervisory Board

bron:
pdf op website: http://www.kiadis.com/wp-content/uploads/2018/04/2017-Financial-Results-PR.pdf